CN104069130A - Allergen obstructing agent for respiratory tract and preparation method thereof - Google Patents
Allergen obstructing agent for respiratory tract and preparation method thereof Download PDFInfo
- Publication number
- CN104069130A CN104069130A CN201310096953.8A CN201310096953A CN104069130A CN 104069130 A CN104069130 A CN 104069130A CN 201310096953 A CN201310096953 A CN 201310096953A CN 104069130 A CN104069130 A CN 104069130A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- allergen
- source barrier
- group
- tract anaphylaxis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of medical instruments, specifically to an allergen obstructing agent for the respiratory tract. The allergen obstructing agent comprises, by weight, 65 to 85% of white oil, 5 to 25% of Vaseline, 5 to 25% of paraffin and 5 to 25% of microcrystalline wax. A preparation method for the allergen obstructing agent comprises the following steps: mixing all the above-mentioned components; heating the obtained mixture to 60 to 120 DEG C and carrying out stirring at the same time; and carrying out cooling after full mixing so as to obtain the finished allergen obstructing agent. According to embodiments in the invention, the allergen obstructing agent can form a protection film with strong adhesion in the nasal cavity to obstruct immediate allergy induced by inhalation allergen and mitigates symptoms of inhalation allergy, thereby achieving a curative effect on prevention of immediate allergy.
Description
Technical field
The present invention relates to medical instruments field, relate in particular to a kind of respiratory tract anaphylaxis source barrier and preparation method thereof.
Background technology
Anaphylactic disease is one of disease that current sickness rate is higher, the crowd of nearly 20%-30% once or was perplexed by this disease, in anaphylactic disease, the most common with imbedibility allergy again, account for greatly 65% of anaphylactic disease, the sickness rate of anaphylactic disease raises year by year, especially at its sickness rate of developed country such as American-European, Japanese higher than developing country.The principal disease being caused by imbedibility anaphylactogen is: allergic asthma, allergic rhinitis, allergic eczema, urticaria, allergic dermatitis, anaphylaxis conjunctivitis etc.In imbedibility anaphylactic disease, the case causing with pollen, acarid, fungus, animal skin etc. is maximum.
Nose in the market has following several feature with anaphylactogen barrier: (1) complicated component, as component comprises cyclodextrin, has obvious discomfort owing to can leave pressed powder in nasal cavity in application; Also have in product and contain the adjuvants such as surfactant polyoxyethylene sorbitan monoleate, antiseptic methyl parahydroxybenzoate and propyl hydroxybenzoate, antioxidant, part composition itself just has sensitization; (2) expensive, the pollen barrier of import, although there is expensive shortcoming in good effect.
Summary of the invention
The invention provides a kind of respiratory tract anaphylaxis source barrier, its respiratory tract disease that pollen-proof, acarid, fungus, animal skin etc. cause in advance, has no side effect, cheap.
The present invention also provides the preparation method of a kind of respiratory tract anaphylaxis source barrier.
The embodiment of the present invention provides a kind of respiratory tract anaphylaxis source barrier, and it comprises the component of following part by weight: white oil 65%-85%, vaseline 5%-25%, paraffin 5%-25%, microwax 5%-25%; When 40 DEG C of described white oils, kinematic viscosity is 70～100m
2/ s.
Preferably, respiratory tract anaphylaxis of the present invention source barrier, comprises the component of following part by weight: white oil 85%, vaseline 5%, paraffin 5%, microwax 5%.
Preferably, respiratory tract anaphylaxis of the present invention source barrier, comprises the component of following part by weight: white oil 70%, vaseline 5%, paraffin 15%, microwax 10%.
Preferably, respiratory tract anaphylaxis of the present invention source barrier, comprises the component of following part by weight: white oil 80%, vaseline 8%, paraffin 5%, microwax 7%.
A kind of method of making described respiratory tract anaphylaxis source barrier is, said components is mixed, and is heated to 60～120 DEG C, stirs cooling getting product after fully mixing simultaneously.
Respiratory tract anaphylaxis source barrier described in the present embodiment, beneficial effect is:
(1) respiratory tract anaphylaxis of the present invention source barrier can form rapidly the extremely strong protecting film of adhesiveness at nasal cavity, intercepts the immediate allergy that imbedibility anaphylactogen brings out;
(2) use above-mentioned respiratory tract anaphylaxis source barrier, can make imbedibility allergic symptom reduce 70%-80%, can make seasonal incidence of pollinosis decline;
(3) respiratory tract anaphylaxis of the present invention source barrier, can effectively intercept imbedibility anaphylactogen and enter in body, thereby reduces the incidence rate of imbedibility allergic disease, reaches the allergic curative effect of prevention imbedibility.
Detailed description of the invention
For making the object, technical solutions and advantages of the present invention clearer, below the present invention is described in further detail.
Embodiment 1:
The present embodiment provides a kind of respiratory tract anaphylaxis source barrier, comprises the component of following part by weight: white oil 85%, vaseline 5%, paraffin 5%, microwax 5%, wherein, when 40 DEG C of white oils, kinematic viscosity is 70～100m
2/ s.
The method of making above-mentioned respiratory tract anaphylaxis source barrier is:
Said components is mixed, be heated to 65 DEG C, stir simultaneously, cooling getting product after fully mixing.
Embodiment 2:
The present embodiment provides a kind of respiratory tract anaphylaxis source barrier, comprises the component of following part by weight: white oil 70%, vaseline 5%, paraffin 15%, microwax 10%, wherein, when 40 DEG C of white oils, kinematic viscosity is 70～100m
2/ s.
The method of making above-mentioned respiratory tract anaphylaxis source barrier is:
Said components is mixed, be heated to 80 DEG C, stir simultaneously, cooling getting product after fully mixing.
Embodiment 3:
The present embodiment provides a kind of respiratory tract anaphylaxis source barrier, comprises the component of following part by weight: white oil 80%, vaseline 8%, paraffin 5%, microwax 7%, wherein, when 40 DEG C of white oils, kinematic viscosity is 70～100m
2/ s.
The method of making above-mentioned respiratory tract anaphylaxis source barrier is:
Said components is mixed, be heated to 100 DEG C, stir simultaneously, cooling getting product after fully mixing.
Utilize above-described embodiment 1～3 composition and the prepared respiratory tract anaphylaxis of method source barrier, Cavia porcellus carried out to following test:
40 Cavia porcelluss, are divided at random:
A group: normal saline injection group (matched group): 8
B group: use artemisiifolia extracting solution injection+ragweed pollen inhalation group: 8
C group: use artemisiifolia extracting solution injection+ragweed pollen suction+respiratory tract anaphylaxis source barrier (adopting embodiment 1 barrier) group: 8
D group: use artemisiifolia extracting solution injection+ragweed pollen suction+respiratory tract anaphylaxis source barrier (adopting embodiment 2 barriers) group: 8
E group: use artemisiifolia extracting solution injection+ragweed pollen suction+respiratory tract anaphylaxis source barrier (adopting embodiment 3 barriers) group: 8
Test method: B, C, every Cavia porcellus of D, E group are extracted injection 0.75ml and equivalent Fo Shi Freund's complete adjuvant (FCA) or Freund's incomplete adjuvant (FIA) with artemisiifolia and carry out artificial immunization.First adopt artemisiifolia to extract injection and add Fo Shi Freund's complete adjuvant, in lumbar injection 0.5ml, extremity subcutaneous (oxter, groin) are respectively injected 0.25ml 1.5ml altogether.After two weeks, change artemisiifolia extraction injection into and add Freund incomplete adjunvant immunity, weekly, continuous two weeks, injected dose, position were with identical first; A group is used normal saline to add equivalent FCA (being changed to FIA after 2 weeks), the same B of method, C, D, E group.
After immunity, 4th week row nasal cavity anaphylactogen excites, rear ragweed pollen allergen is pulverized in preparation, B, C, D, E group are respectively put respectively in tetra-transparent airtight containers of the high 40cm of the wide 60cm of long 60cm, stay a little gas outlet, place and pulverize each 5 grams of rear dry pollen in B, C, D, E container, C, D, E group are smeared respiratory tract anaphylaxis source barrier at nasal vestibule, continue to dry in container, every day 2 times, each 30 minutes, totally 7 days.
Observation item
Sniffle is observed and scoring: start to observe from blowing in container.
Rhinocnesmus symptom score: 0 point: without wiping nose; 1 point: dab nose for several times; 2 points: scratching nose, face is more than, scouring everywhere.
Sneeze symptom score: 0 point: without sneeze; 1 point: 1～3; 2 points: 4～10; 3 points: more than 11.
Thin nasal discharge scoring: 0 point: without watery nasal discharge; 1 point: flow to anterior nares; 2 points: exceed anterior nares; 3 points: watery nasal discharge is had one's face covered with.
Above-mentioned observing time: from observe 30min blowing in container, observe again 30min after the 2h that dries in container.
Nasal secretion smear: after local excitation symptom occurs, wipe secretions smear by little swab stick and carry out Wright dyeing observation.
Statistical method
All measurement datas adopt
represent, the significance of mean difference adopts SPSS statistical software to carry out one factor analysis of variance.
Result is as follows
Sign scoring: through observing contrast, A group is without abnormal sings and symptoms.B group Cavia porcellus occurs again and again grabbing nose both sides with fore paw in 7min left and right from blowing in container starts, and with sneeze sound, most of watery nasal discharge is had one's face covered with, and after 30min, alleviates gradually.C, D, E group respectively has 4 to 5 appearance slightly to grab nose and sneeze outside (scoring is less than 4 points) all without obvious sign.8 scorings of B group are all greater than 6 points, wherein have 3 to occur asthmoid respiration.
Nasal secretion smear eosinophil count: matched group (A group) only has indivedual animals a small amount of eosinophilic granulocyte to be detected in secretions smear, does not use respiratory tract anaphylaxis source barrier group (B group) eosinophilic granulocyte apparently higher than matched group (P<0.05).And be starkly lower than Yu Weiyong group (B group) with respiratory tract anaphylaxis source barrier group eosinophilic granulocyte.
Result of the test is as table one.
Table one nasal cavity excites symptom and sign scoring and eosinophil count table
Note: * and relatively P<0.05 of B group; Acidophil data are 5 high power fields.
Can draw the following conclusions from result:
(1) respiratory tract anaphylaxis of the present invention source barrier can form rapidly the extremely strong protecting film of adhesiveness at nasal cavity, intercepts the immediate allergy that imbedibility anaphylactogen brings out.
(2) use above-mentioned respiratory tract anaphylaxis source barrier, can make imbedibility allergic symptom reduce 70%-80%, can make seasonal incidence of pollinosis decline to some extent.
(3) respiratory tract anaphylaxis of the present invention source barrier, can effectively intercept imbedibility anaphylactogen and enter in body, thereby reduces the incidence rate of imbedibility allergic disease, reaches the allergic curative effect of prevention imbedibility.
Be more than the preferred embodiment of the present invention, it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, can also make some improvements and modifications, these improvements and modifications are also considered as protection scope of the present invention.
Claims (5)
1. a respiratory tract anaphylaxis source barrier, is characterized in that, comprises the component of following part by weight:
White oil 65%-85%, vaseline 5%-25%, paraffin 5%-25%, microwax 5%-25%; When 40 DEG C of described white oils, kinematic viscosity is 70 ~ 100m
2/ s.
2. respiratory tract anaphylaxis source barrier as claimed in claim 1, is characterized in that, comprises the component of following part by weight:
White oil 85%, vaseline 5%, paraffin 5%, microwax 5%.
3. respiratory tract anaphylaxis source barrier as claimed in claim 1, is characterized in that, comprises the component of following part by weight:
White oil 70%, vaseline 5%, paraffin 15%, microwax 10%.
4. respiratory tract anaphylaxis source barrier as claimed in claim 1, is characterized in that, comprises the component of following part by weight:
White oil 80%, vaseline 8%, paraffin 5%, microwax 7%.
5. a method of preparing respiratory tract anaphylaxis source barrier described in claim 1 ~ 4 any one, is characterized in that:
Described component is mixed, be heated to 60 ~ 120 DEG C, stir simultaneously, cooling getting product after fully mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310096953.8A CN104069130A (en) | 2013-03-25 | 2013-03-25 | Allergen obstructing agent for respiratory tract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310096953.8A CN104069130A (en) | 2013-03-25 | 2013-03-25 | Allergen obstructing agent for respiratory tract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104069130A true CN104069130A (en) | 2014-10-01 |
Family
ID=51590996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310096953.8A Pending CN104069130A (en) | 2013-03-25 | 2013-03-25 | Allergen obstructing agent for respiratory tract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104069130A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619436A (en) * | 2014-12-31 | 2018-10-09 | 李德兰 | A kind of preparation method of pharmaceutical composition that treating allergic rhinitis |
| CN112076148A (en) * | 2019-06-12 | 2020-12-15 | 陕西佰傲再生医学有限公司 | Nasal antiallergic gel and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590074A (en) * | 2008-05-27 | 2009-12-02 | 郭进军 | The purposes of carbomer gel on the Polyglucan rhinitis |
| CN101884668A (en) * | 2010-07-06 | 2010-11-17 | 山东赛克赛斯药业科技有限公司 | Composition for preventing and treating allergic rhinitis and preparation method thereof |
| CN101904864A (en) * | 2010-06-24 | 2010-12-08 | 张罗 | Application of silicone oil in preparing allergen retarder |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
-
2013
- 2013-03-25 CN CN201310096953.8A patent/CN104069130A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590074A (en) * | 2008-05-27 | 2009-12-02 | 郭进军 | The purposes of carbomer gel on the Polyglucan rhinitis |
| CN101904864A (en) * | 2010-06-24 | 2010-12-08 | 张罗 | Application of silicone oil in preparing allergen retarder |
| CN101884668A (en) * | 2010-07-06 | 2010-11-17 | 山东赛克赛斯药业科技有限公司 | Composition for preventing and treating allergic rhinitis and preparation method thereof |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619436A (en) * | 2014-12-31 | 2018-10-09 | 李德兰 | A kind of preparation method of pharmaceutical composition that treating allergic rhinitis |
| CN108704090A (en) * | 2014-12-31 | 2018-10-26 | 李德兰 | Treat the preparation method of the pharmaceutical composition of allergic rhinitis |
| CN108704091A (en) * | 2014-12-31 | 2018-10-26 | 李德兰 | A kind of pharmaceutical composition and preparation method thereof for treating allergic rhinitis |
| CN112076148A (en) * | 2019-06-12 | 2020-12-15 | 陕西佰傲再生医学有限公司 | Nasal antiallergic gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011153937A1 (en) | Herbe dendrobii extract, its preparation method and use thereof | |
| CN109475564A (en) | The composition for being used to prevent or treat inflammatory dermatoses or serious pruritus containing water-soluble ursodesoxycholic acid | |
| CN104069130A (en) | Allergen obstructing agent for respiratory tract and preparation method thereof | |
| CN103100115B (en) | Obstetric canal lubrication composition | |
| CN106974864A (en) | A kind of facial mask of delay skin aging | |
| WO2008066644A1 (en) | Methods of treating epiphora | |
| CN101766647A (en) | Purpose of montmorillonite in treating allergic rhinitis and skin allergy | |
| CN101829154B (en) | Preparation method of medicine composition for preventing and treating asthma | |
| CN110354011A (en) | A kind of bite by mosquitos is releived liquid and preparation method thereof | |
| CN103816083A (en) | Acne-removing mark-removing transparent emulsion containing basic fibroblast growth factor and preparation method thereof | |
| CN107441033A (en) | A kind of deep moisturizing skin care item and preparation method thereof | |
| CN109172386A (en) | A kind of compound moisturizing hydrogel | |
| CN104189081B (en) | It is a kind of to be used to treat Chinese medicine composition of allergic rhinitis and preparation method thereof | |
| CN101904864B (en) | Application of silicone oil in preparing allergen retarder | |
| CN103860543B (en) | Isoforskolin is in the application preventing and treating in chronic obstructive pulmonary disease | |
| CN107823337A (en) | A kind of allergic rhinitis oil formula and its preparation technology | |
| CN105055528A (en) | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof | |
| WO2008063555A3 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
| CN112891388B (en) | Composite plant extract and preparation method and application thereof | |
| JP6478917B2 (en) | Antigen processing and utilization of processed antigens | |
| US10993958B1 (en) | Aldehyde functional monoterpenoids for the treatment of coronavirus infection | |
| US11197874B2 (en) | Use of an amphoteric chelating agent for preventing contact allergies | |
| CN115400077B (en) | Application of sea dragon gecko oral liquid in preparation of medicines for treating allergic rhinitis | |
| JP2010143887A (en) | Therapeutic agent and/or prophylactic agent for allergic disease | |
| CN101791399A (en) | Water-containing liquid allergic reaction bacterin preparation for mouth mucosa drug administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141001 |